

SPECIALTY QUANTITY LIMIT PROGRAM

HUMIRA (adalimumab)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Humira (adalimumab) 10 mg/0.1 mL single-use prefilled syringe	2 syringes per 28 days	<p>RA/PsA/AS</p> <ul style="list-style-type: none"> 40 mg every other week For patients not taking concomitant methotrexate: may increase to 40 mg every week if needed <p>PJIA/Pediatric uveitis (2 years and up)</p> <ul style="list-style-type: none"> 10 kg to < 15 kg: 10 mg every other week 15 kg to < 30 kg: 20 mg every other weeks ≥ 30 kg: 40 mg every other week <p>Pediatric CD (6 years and up)</p> <ul style="list-style-type: none"> 17 kg to < 40 kg: loading doses of 80 mg on day 1 and 40 mg two weeks later (day 15); maintenance dose (starting at week 4 (day 29) of 20 mg every other week ≥ 40 kg: loading doses of 160 mg on day 1 (given in one day or split over two consecutive days) and 80 mg two weeks later (day 15); maintenance dose starting at week 4 (day 29) of 40 mg every other week <p>Adult CD and UC</p> <ul style="list-style-type: none"> Loading doses: 160 mg on day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (day 15) Maintenance dose: two weeks later (day 29), 40 mg every other week
Humira (adalimumab) 10 mg/0.2 mL single-use prefilled syringe	2 syringes per 28 days	
Humira (adalimumab) 20 mg/0.2 mL single-use prefilled syringe	2 syringes per 28 days	
Humira (adalimumab) 20 mg/0.4 mL single-use prefilled syringe	2 syringes per 28 days	
Humira (adalimumab) 40 mg/0.4 mL single-use prefilled syringe/pen	4 syringes/pens per 28 days	
Humira (adalimumab) 40 mg/0.8 mL single-use prefilled syringe/pen	4 syringes/pens per 28 days	
Humira (adalimumab) 40 mg/0.8 mL Pediatric Crohn's Disease Starter Pack	6 syringes per 28 days	
Humira (adalimumab) 80 mg/0.8 mL Pediatric Crohn's Disease Starter Pack	3 syringes per 28 days	
Humira (adalimumab) 80 mg/0.8 mL and 40 mg/0.4 mL Pediatric Crohn's Disease Starter Pack	2 syringes per 28 days	

Reference number
2270-H

Medication	Standard Limit	FDA-recommended dosing
Humira (adalimumab) 40 mg/0.8 mL pen Crohn's Disease, Ulcerative Colitis, or Hidradenitis Suppurativa Starter Pack	6 pens per 28 days	<p>Plaque psoriasis/ uveitis</p> <ul style="list-style-type: none"> 80 mg, followed by 40 mg every other week starting one week after the initial dose of 80 mg <p>Adolescent hidradenitis suppurativa (12 years and up)</p> <ul style="list-style-type: none"> 30 kg to < 60 kg: 80 mg on day 1, 40 mg on day 8 and subsequent doses 40 mg every other week ≥ 60 kg: Follow adult dosing <p>Adult hidradenitis suppurativa</p> <ul style="list-style-type: none"> Loading doses: 160 mg on day 1 (given in one day or split over two consecutive days), followed by 80 mg two weeks later (day 15) Maintenance dose: begin 40 mg every week two weeks later (day 29)
Humira (adalimumab) 80 mg/0.8 mL pen Crohn's Disease, Ulcerative Colitis, or Hidradenitis Suppurativa Starter Pack	3 pens per 28 days	
Humira (adalimumab) 40 mg/0.8 mL pen Psoriasis/Uveitis/Adolescent Hidradenitis Suppurativa Starter Pack	4 pens per 28 days	
Humira (adalimumab) 80 mg/0.8 mL and 40 mg/0.4 mL Psoriasis/Uveitis/Adolescent Hidradenitis Suppurativa Starter Pack	3 pens per 28 days	

Abbreviations: RA = rheumatoid arthritis; PsA = psoriatic arthritis; AS = ankylosing spondylitis; PJIA = polyarticular juvenile idiopathic arthritis; CD = Crohn's disease; UC = ulcerative colitis

III. REFERENCE

1. Humira [package insert]. North Chicago, IL: AbbVie Inc.; October 2018.